Evidence map›Paper›PMID 32306814›Full record

ArticleJournal of the American Heart Association2020

Smad3 Regulates Neuropilin 2 Transcription by Binding to its 5' Untranslated Region.

Xiujie Xie, Go Urabe, Lynn Marcho, Corey Williams, Lian-Wang Guo, K Craig Kent

Open access · goldAbstract read
In one paragraph

Article in Journal of the American Heart Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. NovelbioRxiv : the preprint server for biology · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Impact of the transforming growth factor-β pathway on vascular restenosis and its mechanism.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023
    Article
  7. Review
  8. Article
  9. Emerging Roles for Neuropilin-2 in Cardiovascular Disease.International journal of molecular sciences · 2020
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Xiujie XieDepartment of Surgery College of Medicine The Ohio State University Columbus OH.
Go UrabeDepartment of Surgery College of Medicine The Ohio State University Columbus OH.
Lynn MarchoDepartment of Surgery College of Medicine The Ohio State University Columbus OH.
Corey WilliamsDepartment of Surgery College of Medicine The Ohio State University Columbus OH.
Lian-Wang GuoDepartment of Surgery College of Medicine The Ohio State University Columbus OH.
K Craig KentDepartment of Surgery College of Medicine The Ohio State University Columbus OH.
The Ohio State University · USThe Ohio State University Wexner Medical Center · US

Funding

TGF-Beta in Intimal Hyperplasia after Vascular BypassR01HL068673 · NHLBI · WEILL MEDICAL COLLEGE OF CORNELL UNIV · PI KENT, K CRAIG · 2002 to 2017
$4.9M
Targeting PERK: An Endothelium-Protective Stent-Free Strategy for Mitigation of Intimal Hyperplasia After Vascular SurgeryR01HL143469 · NHLBI · UNIVERSITY OF VIRGINIA · PI GONG, SHAOQIN -, GUO, LIANWANG · 2018 to 2021
$2.4M
Development of unimolecular nanoparticle-mediated periadventitial drug delivery system for sustained and targeted inhibition of intimal hyperplasia following open vascular reconstructionR01HL129785 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI GUO, LIANWANG, KENT, K CRAIG · 2016 to 2019
$2.0M
BET Bromodomain proteins as Novel Epigenetic Targets for prevention of Intimal Hyperplasia after Vascular SurgeryR01HL133665 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI GUO, LIANWANG · 2016 to 2019
$1.6M
NHLBI NIH HHS R01 HL068673NHLBI NIH HHS R01 HL129785NHLBI NIH HHS R01 HL133665NHLBI NIH HHS R01 HL143469
6 · The paper itself

Abstract

Background Vascular smooth muscle cell phenotypic change and consequential intimal hyperplasia (IH) cause arterial stenosis and posttreatment restenosis. Smad3 is a master transcription factor, yet its underlying functional mechanisms in this disease context are not well defined. Methods and Results In cultured smooth muscle cells, Smad3 silencing and overexpression respectively reduced and increased the mRNA and protein of NRP2 (neuropilin 2), a recently reported pro-IH signaling factor. Smad3 silencing attenuated pro-IH smooth muscle cell phenotypes including proliferation, migration, and dedifferentiation (reduced smooth muscle α-actin). While increased Smad3 enhanced these phenotypes, NRP2 silencing abolished this enhancement. Interestingly, the 5' untranslated region but not the promoter of NRP2 was indispensable for Smad3-enhanced transcriptional activity (luciferase assay); both chromatin immunoprecipitation and electrophoretic mobility shift assay showed predominant Smad3 binding in the +51 to +78 bp region of NRP2's 5' untranslated region. In vivo, Smad3 haploinsufficiency reduced NRP2 (immunostaining) and IH (by 47%) in wire-injured mouse femoral arteries. Conclusions Smad3 controls NRP2 expression by occupying its 5' untranslated region in promoting smooth muscle cell phenotypic change in vitro. This and in vivo results shed new light on the long-debated role of Smad3 in IH.

Indexed as

5' Untranslated RegionsTranscription, GeneticAnimalsBinding SitesCell MovementCell ProliferationCells, CulturedDisease Models, AnimalHumansMaleMice, KnockoutMuscle, Smooth, VascularMyocytes, Smooth MuscleNeointimaNeuropilin-2Protein Binding5' Untranslated RegionsNeuropilin-2neuropilin-2, humanSmad3 ProteinSMAD3 protein, humanSmad3 protein, mouseTGFB1 protein, humanTransforming Growth Factor beta15′ untranslated regionintimal hyperplasiaNRP2Smad3Smad3‐haploinsufficient mice

Identifiers

PMID32306814
PMCPMC7428547
OpenAlexW3016902653

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.